



[search](#)
[» Professionals](#)
[» Patients](#)
[» Products](#)
[» Reimbursement](#)
[» Business Development](#)

Visipaque

Home

Visipaque

- [Overview](#)
- [Indications](#)
- [Prescribing Information](#)
- [Pharmacy Bulk Pack PI](#)
- [Material Safety Data Sheet](#)
- [Packaging](#)



Visipaque(iodixanol)

At all iodine concentrations, is the only isosmolar contrast medium available for intravascular use. Is indicated for Contrast Enhanced Computer Tomography (CECT) imaging of the head and body.

Visipaque Press Release

Federal Trial Court Rebuffs Bracco's Claim for Billions of Dollars in Damages Against GE Healthcare for Advertising of X-Ray Contrast Agent. Court finds published clinical studies sponsored by GEHC were sound

» [Learn more](#)

Visipaque Corrective Advertisement

Product Highlights

- The only isosmolar contrast medium (IOCM) available in the United States¹
- Patient-procedure friendly, particularly when risk is high³
- Formulated with sodium and calcium at biologic levels⁴
- Provides excellent diagnostic efficacy^{2,5}

ISOSMOLAR
VISIPAQUE™
(IODIXANOL) INJECTION

Product Ordering

1 800 292 8514

8:00 am to 7:30 pm ET
Call toll-free to place an order or to get pricing information.

Sales Rep. Locator

Enter a zip code to locate an imaging sales representative in your area.

You can also locate an imaging sales representative by calling 1

- Helps improve efficiency, and maximize contrast for high-quality images and diagnostic outcomes⁶

800 654 0118

Product Description

Launched in 1996, VISIPAQUE is the only isosmolar contrast medium (IOCM) available in the U.S. With an osmolality equal to that of blood, VISIPAQUE was designed for patient safety and comfort. VISIPAQUE is also the only contrast medium formulated with sodium and calcium in a ratio equivalent to blood. In 1997, VISIPAQUE received FDA approval for use in children over one year of age. With an excellent safety profile, VISIPAQUE is approved for a broad range of diagnostic procedures requiring intravascular contrast, such as coronary angiography, CT, IVP, and venography.

References: 1. Data on file, GE Healthcare. 2. Klow NE, Levorstad K, Berg Kj, et al. Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects. Acta Radiol. 1993;34:72-77. 3. Davidson Cj, Laskey WK, Hermiller jB, et al. Randomized trial of contrast media utilization in high risk PTCA: The COURT Trial. Circulation. 2000;101:2172-2177. 4. VISIPAQUE Prescribing Information. 5. Hill jA, Cohen MB, Kou WH, et al. Iodixanol, a new isosmotic non ionic contrast agent compared to iohexol in cardiac angiography. Am J Cardiol. 1994;74:57-63. 6. Spencer CM, Goa KL. Iodixanol: a review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an X-ray contrast medium. Drugs. 1996;52:899-927.

NOT FOR INTRATHECAL USE. All nonionic, iodinated contrast media currently available inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly

**CONTRAST MEDIA
WARMER LOG BOOK**[Download Logbook](#)

when large doses are administered.

[GE Healthcare](#) | [Professionals](#) | [Patients](#) | [Products](#) | [Reimbursement](#) | [Business Development](#)

[About](#) | [HIPAA](#) | [Safe Harbor](#) | [Contact Us](#) | [Privacy Policy](#) | [Accessibility Statement](#) | [Terms and Conditions](#) | [Customer Relations Code of Conduct](#) | [California Declaration of Compliance](#)

The information in this web site is intended for use only by customers, patients and health care professionals in the United States.

Copyright General Electric Company 1997-2009